written on 15.04.2014

Roche cancer drugs Perjeta and Kadcyla drive strong Q1 results


Swiss drug giant Roche has hit the ground running in 2014, announcing today that quick uptake of its new cancer drugs helped drive first-quarter sales up 5% year-over-year in constant currencies to 11.5 billion Swiss francs ($13 billion).